Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So, we started Monday at $14.41, before the big drop on the vaccine news. Was that big drop just an excuse to give the shorts some room to cover? Are we now set for a run tomorrow and Monday? Is this the time we actually increase pps after earnings? Or are we going to get played once again?
How can you trust the market when we have been burned on this stock two times before on earnings report reactions? What trick is sitting out there waiting to be pulled this time?
Opti
Co-Diagnostics, Inc. CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction
SALT LAKE CITY, Nov. 11, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that a recent Company whitepaper demonstrates that the CoPrimer™ platform technology can be used to identify the presence of SARS-CoV-2 in human saliva samples without first requiring RNA extraction of the sample, and can do so while providing low limits of detection.
The technical advance featured in the whitepaper, found here, was the result of a study into the compatibility of CoPrimer technology with detection of SARS-CoV-2 directly from raw saliva. Various CoPrimer assay configurations were used to consistently detect SARS-CoV-2 in minimally processed saliva in the whitepaper, which concludes that CoPrimers provide a robust platform for the development of such tests.
Dwight Egan, CEO of Co-Diagnostics, commented, "The market for high-throughput, cost-effective COVID-19 tests continues to be strong, and eliminating the costly and time-consuming RNA extraction step allows for even greater speed and economic advantages. We believe the conclusions of this whitepaper speak to the strength, innovation, and flexibility of our CoPrimer platform not just as it relates to creating improved testing technology for COVID-19, but also additional possibilities to implement CoPrimers in various other diagnostic applications. Our next steps include incorporating extraction-free saliva direct tests into the Company product offerings, including those for COVID-19, so they can be available to our customer base world-wide."
Release of the Company whitepaper follows recent news that Clinical Reference Laboratory (CRL) is now selling its CRL Rapid Response saliva-based COVID-19 RT-PCR test directly to consumers. The CRL announcement states that the test uses CoPrimer probes and primers developed by Co-Diagnostics with high degrees of sensitivity and specificity, and a simple saliva collection device that can be administered in virtually any setting, with results in typically 24 hours that are delivered via a secure online computer or mobile device platform.
Mr. Egan continued, "CRL has been an invaluable customer and partner in providing high-quality molecular diagnostic COVID-19 tests to individuals and organizations across the country, helping to facilitate the safe reopening of schools, business, and other organizations. We are pleased that its CRL Rapid Response test will now be even more widely available to consumers online."
Co-Diagnostics' existing CE-marked and FDA EUA Logix Smart COVID-19 test is available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA), and is authorized to be used for the diagnosis of SARS-CoV-2, the virus that causes COVID-19, in the US and many other countries.
https://news.codiagnostics.com/2020-11-11-Co-Diagnostics-Inc-CoPrimers-TM-Shown-to-be-Effective-in-COVID-19-Saliva-PCR-Tests-Without-Sample-Extraction
Opti
Co-Diagnostics, Inc. Announces Q3 2020 Earnings Release Date and Earnings Webcast
SALT LAKE CITY, Nov. 10, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will release its third quarter 2020 earnings on November 16, 2020 after the close of trading on that day, and will hold an earnings call at 4:30 pm EDT. The call is expected to consist of prepared remarks by Company CEO Dwight Egan.
Opti
The consensus of the 3 analysts covering CODX for 3rd quarter 2020 is a per share value of USD .63.
Mean Estimate: USD 0.63
High Estimate: USD 0.87
Low Estimate: USD 0.49
Annual Earnings and Estimates
From my eTrade account
Opti
There also is the addition of a dividend calculator on the web page
Opti
chatter that Company may be considering issuance of a dividend.
Interesting.
Opti
The shorts walk this down on low volume. Oh, how I wish some institutional buyers would jump in after hours and buy 5 or 6 million shares and totally trap the evil shorts.
Opti
Agreement coming on national testing program.
While many differences remain unresolved, Pelosi and Treasury Secretary Steven Mnuchin had been making progress on the issue of a national Covid-19 testing strategy, on which Pelosi insisted. The speaker said late Friday afternoon her office was still awaiting promised changes to nearly-agreed-upon language from Mnuchin on that score.
Pelosi and Mnuchin are expected to talk again on stimulus Saturday at 7:30 p.m., a House Democratic aide said. “We can’t speak before we see where we’re going on the language” on testing, Pelosi said on MSNBC.
https://www.bloomberg.com/news/articles/2020-10-16/pelosi-flags-poison-pills-in-stimulus-talks-testing-deal-nears?srnd=premium
Opti
Unfortunately, none.
My pure guess is $8.
Opti
Volume 794,400
wow
opti
Inovio down 5% as Citron Research sees over 80% downside risk
Sep. 29, 2020 2:38 PM ET|About: Inovio Pharmaceuticals... (INO)|By: Douglas W. House, SA News Editor
Noted short seller Citron Research sees 83% downside risk (price target = $2) in Inovio Pharmaceuticals (INO -4.9%) on the heels of the FDA's partial clinical hold on its planned Phase 2/3 clinical trial evaluating COVID-19 vaccine candidate INO-4800 and the Cellectra 2000 delivery device.
Citron believes the issue is Chemistry, Manufacturing and Controls data. Specifically, the company switched manufacturers mid-development which prompted the agency to reassess the processes and procedures to ensure that the drug substance is unchanged.
Citron also reminds investors that the company has no track record of advancing products into the marketplace and it lags all of the major vaccine developers.
Quant rating is Neutral.
read this article: https://www.globenewswire.com/news-release/2020/08/20/2081387/0/en/What-Facts-Got-to-Do-with-It.html
from the article:
When Co-Diagnostics announced in the middle of Q2 that it had brought in $1.5 million for Q1 (alone impressive, given its revenue for the entirety of 2019 was in the neighborhood of $250,000), and that it had seen mid-quarter revenue in the $16 million range, the market had to guess where CODX was going to go from there. And guess is exactly what they did. This is not a company with years of profitability, with one successful quarter after another displaying a predictable pattern of where it will go next. So, analysts looked at the numbers, closed their eyes, and chose some figures. They could have just as easily guessed lower, but they did not. If they had, CODX headlines would be blowing up about this unheard-of success story, all while posting the exact same results.
So what is more important: falling short of arbitrary analyst estimates, based on forecasts which amounted to little more than guesswork, or the fact that this company went from $61,000 of revenue in the same period last year to an astounding $12 million of EARNINGS this year?
Breaking it down even further, what does $0.43 earnings per share mean? At a very modest 20 times earnings, $0.43 stretched out over 4 quarters translates to a $34.00 stock price. $14.53 per share makes CODX trading at an extremely undervalued 8.4 times earnings. Based on the Q2 results, CODX is incredibly fundamentally sound. You can bet that when the dust settles, fund managers looking for a company that is undervalued based on pure fundamentals will recognize this fact.
CODX announced in their recent earnings call release that they have recorded $50 million in sales orders YTD so far, which was regarded by some as a little opaque. What does this figure mean? Company revenue YTD by the end of Q2 was $25.5 million, and the CFO reported in their recent earnings call that Q3 revenue to date was $8 million. This leaves a balance of $16.5 million worth of sales in process for the quarter to date. What is more, in response to a question by an analyst in that call regarding whether sales are slowing down, the CFO indicated that the opposite is true, and sales volume is ramping up. So depending on the length of the sale cycle and other orders yet to be taken for the quarter, it is possible to see revenues equivalent to Q2. Even in the event COVID-19 sales dip in the summer before the ramp-up to flu season, it is important to keep in mind that CODX profits are driven by their robust coronavirus test margins of 70%. This is going to be a profitable company for the foreseeable future and beyond, something several of their competitors could only dream of saying.
Among the reasons to be excited about revenues throughout the end of the year is the company’s respiratory disease panel that they discussed as part of their earnings announcement. Put the Flu A, Flu B, and COVID-19 “ABC” respiratory panel in perspective: as important as the coronavirus test has been for CODX, companies like GenMark and BioFire have made tremendous volumes of sales of tests for respiratory diseases for years. We know a need for such a product exists, because no less than the CDC itself thinks so as well. This is a market from which CODX now stands to see even more revenue, especially with its growing network of CLIA lab customers.
Speaking of CLIA customers, it was reported over the weekend that Los Angeles-area schools are planning on testing 700,000 students and 75,000 employees. Buried deep at the end of that article are the two companies who will be performing the tests, one of which is Clinical Reference Laboratory, in Kansas. Followers of CODX will immediately recognize CRL as the company that recently announced it had received FDA EUA for a self-collected saliva-based coronavirus test, which is analyzed using CODX technology. And this sizable and respectable model for returning to school is just one contract, for just one CODX laboratory customer.
Still the best article out there: https://www.globenewswire.com/news-release/2020/08/20/2081387/0/en/What-Facts-Got-to-Do-with-It.html
Opti
I have held and watched closely three stocks over the last 6 months:
INO, APT, and CODX. The three of them are like a close Indianapolis 500 race. One week one is ahead and another week one of the others. I have owned large shares of APT and CODX and both have peaked and crashed.
Current prices are
INO $10.08
APT $14.05
CODX $13.71
CODX is closing on APT fast and may overtake APT next week.
Opti
Posted on 9/08/20
We have probably about 90 million in share volume to make up to get us back above $26. Slow steady climb over a couple of weeks would be sweet.
Opti
so, we are slowly getting the needed volume.
Manipulation hurts on the way down but feels better when we are climbing back up.
Anyone else see the total manipulation? So, who is it that is running the show?
Opti
Co-Diagnostics gains new life after Test Utah with validation study
https://www.abc4.com/news/co-diagnostics-gains-new-life-after-test-utah-with-validation-study/
Opti
I recently asked John how much it would cost to finish the audit and file for re-registration, offering to consider paying for the process, since I have $47,000 invested. Still hoping for a response.
Opti
US Coronavirus: The US needs 200 million tests a month to reel in Covid-19 pandemic, report says
By Theresa Waldrop and Maggie Fox, CNN 3 hrs ago
https://www.msn.com/en-us/health/medical/us-coronavirus-the-us-needs-200-million-tests-a-month-to-reel-in-covid-19-pandemic-report-says/ar-BB18QG7h?ocid=msedgdhp
Opti
The average for tech stocks is 21x earnings, and earnings are going up
We have probably about 90 million in share volume to make up to get us back above $26. Slow steady climb over a couple of weeks would be sweet.
Opti
$3.80 per share earnings? Good estimate, but probably a bit low on the annual basis.
Opti
NY launches school Covid-19 'report card'
Sep. 8, 2020 12:09 PM ET|About: Laboratory Corporation of A... (LH)|By: Brad Olesen, SA News Editor
NY Governor Cuomo, in a briefing in NYC, announces that as part of the efforts related to school reopenings, NY will now require the publication of a daily "report card" for every school to give parents and teachers "confidence" about where their school stands in terms of potential outbreaks.
The site will be run by the NY Department of Health, absorbing data from a variety of sources, including testing centers and schools so that the information is not reliant on the school districts' dissemination of data. The site can be found here: https://schoolcovidreportcard.health.ny.gov/
The site is designed to show the positivity rate, number of tests conducted, and whether a student or teacher who tested positive did so in a remote learning capacity, or whether it was in-person.
Stocks involved in Covid-19 testing include Laboratory Corp (NYSE:LH), Abbott Labs (NYSE:ABT), Quest Diagnostics (NYSE:DGX), Co-Diagnostics (NASDAQ:CODX), Fulgent Genetics (NASDAQ:FLGT) and Opko's BioReference (NASDAQ:OPK), to name a few.
https://seekingalpha.com/news/3612186-ny-launches-school-covidminus-19-report-card?utm_medium=email&utm_source=seeking_alpha&mail_subject=codx-ny-launches-school-covid-19-report-card&utm_campaign=rta-stock-news&utm_content=link-3
Opti
You're right, the pps should be around $26, with an increase above $40 based on future earnings.
JP
Real contracts equal real money. Earnings increase share price.
Opti
PolarityTE teams up with Co-Diagnostics to expand COVID-19 testing platform
Sep. 8, 2020 9:03 AM ET|About: Co-Diagnostics, Inc. (CODX)|By: Mamta Mayani, SA News Editor
PolarityTE (NASDAQ:PTE) subsidiary, Arches Research has entered into a strategic partnership with Co-Diagnostics (NASDAQ:CODX) to expand COVID-19 testing operations.
Under the agreement, Arches will provide COVID-19 testing for customers referred by Co-Diagnostics and, to support additional demand, latter will provide testing equipment in exchange for commitment to use only Co-Diagnostics' tests on the equipment.
Arches has previously been performing COVID-19 testing using CODX's Logix Smart COVID-19 test kit.
PTE +7% whereas CODX is up 8% premarket.
https://seekingalpha.com/news/3612086-polarityte-teams-up-co-diagnostics-to-expand-covidminus-19-testing-platform?utm_medium=email&utm_source=seeking_alpha&mail_subject=codx-polarityte-teams-up-with-co-diagnostics-to-expand-covid-19-testing-platform&utm_campaign=rta-stock-news&utm_content=link-3
Opti
Co-Diagnostics, Inc. Enters into Agreement with Arches Research to Expand COVID-19 Testing Services
by Co-Diagnostics | Sep 8, 2020 | News Release |
Salt Lake City, Utah – September 8, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today announced that it has entered into an agreement with Arches Research, Inc, a CLIA laboratory and subsidiary of Polarity TE, Inc, (Nasdaq: PTE), to expand Arches’ COVID-19 testing services using Co-Diagnostics’ Logix Smart™ COVID-19 test kit.
Arches Research began using Co-Diagnostics’ tests for its customers earlier this year. The announcement follows news last week of additional, independent third-party validation of the Company’s test, supporting its performance characteristics and value in helping communities, schools, and workplaces to re-open safely.
Dwight Egan, CEO of Co-Diagnostics, remarked, “We are pleased to have this opportunity to further expand our relationship with one of our valued CLIA lab clients to help meet demand for COVID-19 testing. Arches has been an important customer in the ongoing battle against the coronavirus, and we expect this agreement will also create opportunities for sales of additional molecular diagnostic products in our development pipeline, including our upcoming Logix Smart Flu A/Flu B/COVID-19 test kit.”
The CE-marked and FDA EUA Co-Diagnostics Logix Smart COVID-19 test is currently available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA), and is authorized to be used for the diagnosis of SARS-CoV-2, the virus that causes COVID-19, in the US and many other countries.
Arches received a Clinical Laboratory Improvement Amendments of 1988 (CLIA) certificate of registration at the end of April and began testing for COVID-19 shortly thereafter. CLIA is regulated by the Centers for Medicare & Medicaid Services (CMS) with a primary goal to ensure quality laboratory testing.
http://codiagnostics.com/co-diagnostics-enters-into-agreement-with-arches/
Opti
CODX officials need to open discussions with big pharma about a buyout or merger and set a price around $35, just to get the shorting hedge funds off their backs. Actually, I would love to see a weekend buyout just to burn the hedge funds and send them into bankruptcy.
Opti
Co-Diagnostics COVID-19 Test Independently Validated By US-based Distributor
https://www.globenewswire.com/news-release/2020/09/03/2088736/0/en/Co-Diagnostics-COVID-19-Test-Independently-Validated-By-US-based-Distributor.html
September 03, 2020 14:06 ET | Source: TNG Dx
NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TNG Dx, LLC, a wholesale distribution and technology solutions company, announced the results of an independent validation study of Co-Diagnostics Logix Smart™ COVID-19 Test kit, a reverse transcriptase polymerase chain reaction (RT-PCR) test that uses samples swabbed from the nose, pharynx, or saliva. The study tested 93 samples of COVID-19 and 93 samples of Influenza B, with results showing 100% sensitivity, 100% selectivity, and a Limit of Detection (LOD) of less than 1.2 viral genome copies per microliter (ul).
TNG Dx identified the Logix Smart™ COVID-19 test as one of the most promising tests to address national and global testing needs. Its patented CoPrimer™ technology, which has demonstrated the ability to reduce amplification errors by a factor of 2.5 million, coupled with use of a single genetic target, makes it ideal for multiplexed solutions. In addition, the test is universal for most open-platform qPCR machines and other equipment. However, the test’s performance was challenged by certain outside parties. In response, TNG Dx contacted Co-Diagnostics, Inc. to offer its independent validation and assessment of the Logix Smart™ test.
TNG Dx contracted Dr. Meghan Lockard, an independent consultant in New York City who has advised companies in the life sciences and health technologies, to validate the test’s metrics and help determine if the test could be used to develop a protocol for large scale, asymptomatic screening by increasing the existing test’s throughput 10-fold while reducing its cost commensurately. Dr. Lockard’s work confirmed the test’s performance characteristics and even found the LOD to be much lower than that outlined in the test’s submission to the FDA for emergency use authorization. More importantly, Dr. Lockard’s protocol makes it feasible to support running millions of tests per day with accurate results even if patient samples have low viral loads.
The results of Dr. Lockard’s findings will be published in a press release to follow in the coming days.
Dr. Lockard commented, “At the beginning of the pandemic, we did not know anything about this novel virus. We did not know that so many patients would be asymptomatic, or what viral loads would be pathologically relevant, a topic that is still surrounded by controversy. It seems that Co-Diagnostics did the responsible thing and reported a very conservative level of detection in their FDA filing.” 1.2 copies per microliter was the lowest concentration Dr. Lockard assayed, and additional tests are currently underway to rigorously determine whether the LOD may even be lower.
Dr. Lockard further remarked, “The Logix Smart COVID-19 RT-PCR test performs well and I believe clinical testing programs should feel confident in its immediate adoption. The test can also enable alterations in testing pipelines that fundamentally improve throughput and cost.”
She continues, “We will immediately begin working with outside labs to validate our findings for large-scale asymptomatic sampling. This test could be one of the key technologies to large-scale testing strategies where 99% or more of patient samples may be negative. A testing program like this is necessary to ensure public safety as we reopen businesses, schools, and public institutions.”
Co-Diagnostics reports to have the capacity to manufacture up to 3 million tests per week and thinking ahead, procured substantial inventory to meet the country’s needs. The Company states that they have yet to be affected by supply chain issues.
About Dr. Meghan Lockard
Dr. Meghan A. Lockard earned her Ph.D. from the Rockefeller University in New York City, conducting her thesis in the laboratory of Dr. Cori Bargmann. In business, Dr. Lockard is an independent advisor specializing in early phase startups, small businesses, and non-profits in the life sciences and health tech space. She has advised companies on the development of a vaccine for fentanyl, soft robotic catheters to map atrial fibrillation, and AI for melanoma diagnosis, to name a few. Dr. Lockard teaches at Fordham University, Lincoln Center. She is on the editorial board for the journal Intelligence-Based Medicine, a scientific journal focused on applications of machine learning and AI in clinical practice. Prior, Dr. Lockard worked at Los Alamos National Laboratory's Advanced Measurement Science Group in the Bioscience Division, where she co-patented two inventions. Dr. Lockard is currently engaged as a science advisor for TNG Dx.
About TNG Dx, LLC
TNG Dx, LLC is a wholesale distribution and technology solutions company formed to address unmet needs related to the Coronavirus pandemic. TNG Dx combines leading scientific talent with sales and execution capabilities. Its partners have vast experience across numerous verticals, including Healthcare, Manufacturing, Food and Beverage, Aviation, Retail, Energy, Manufacturing, Retail, Financial Services, and Real Estate. TNG Dx can be reached for comment at contact@texasnyg.com
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
SOURCE TNG Dx LLC
Welcome to the club. Praying we have green days ahead.
Opti
Significant news and a 20 million volume day will propel us back to $23. Watch for the beginning of a slow climb in 2 weeks.
Opti
Shorts cannot make money if they don't eventually cover, so this has to end sometime. Hard to figure but nothing I can do now but hold and pray.
Opti
Boy would I love to see CODX CEO give a speech like this...SRNE CEO warning shorts.
https://mobile.twitter.com/RagingBull/status/1298369002872410112
Opti
Not helpful news from Seeking Alpha.
Inovio: A Viable Short, Falling Behind The Leaders In COVID-19 Vaccine Development
Aug. 25, 2020 3:08 PM ET
Summary
INO is up over 300% year-to-date despite the recent sell off.
INO-4800 got out of the blocks quickly, but the pace of development has faded a little.
INO hasn't confirmed the details of its late-stage study of INO-4800, the market likely wants certainty that INO is still very much in this race.
https://seekingalpha.com/article/4370685-inovio-viable-short-falling-behind-leaders-in-covidminus-19-vaccine-development?utm_medium=email&utm_source=seeking_alpha#alt1&mail_subject=ino-inovio-falling-behind-the-leaders-in-covid-19-vaccine-development-a-very-viable-short&utm_campaign=rta-stock-article&utm_content=link-2
Opti
Co-Diagnostics, Inc. To Discuss Recent Company Growth and Upcoming Expansion Plans at H.C. Wainwright Global Investment Conference
6:30 AM ET 8/25/20 | Dow Jones
Related Quotes
4:00 PM ET 8/24/20
Symbol Last % Chg
CODX
12.57 0.00%
Real time quote.
SALT LAKE CITY, Aug. 25, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Company CEO Dwight Egan will be discussing the Company's significant growth, profitability, and future objectives at H.C. Wainwright's 22(nd) Annual Global Investment Conference on Monday, September 14(th) at 10:00 ET.
Co-Diagnostics continues to achieve substantial growth, driven by domestic and international sales of its high-throughput Logix Smart COVID-19 test, as Q2 2020 revenue increased 1,503% over Q1 2020 to over $24 million, and earnings surged from a loss in the previous quarter to over $12 million. Mr. Egan will provide a recap of the Company's financial, scientific, and regulatory accomplishments in the context of the ongoing global coronavirus health crisis, as well as outline how Co-Diagnostics expects to remain a leader in cutting-edge molecular diagnostics solutions.
"Co-Diagnostics has been at the forefront of the battle against the coronavirus since January, and our innovative design platform and patented CoPrimer(TM) technology have allowed us to stand out and enabled our rapid rise to impressive sales and profitability," remarked Mr. Egan. "We believe both our outstanding financial and scientific achievements, as well as our regulatory authorizations by the US FDA, India, European Community and others, and our expanded distributor network covering nearly 50 countries and over 25 states have all positioned the Company for extraordinary future growth."
Participants in the September 14-16 conference, which will be held virtually, include public companies, industry executives, business development executives, institutional investors, and more. Co-Diagnostics invites participating fund managers and other investing institutions to schedule one-on-one meetings with the Company, which may be booked via H.C. Wainwright after registering to attend.
Additional details will be posted to the Company's Events and Presentation page closer to the date of the conference. More information about the conference may be found here.
Opti
I wish I had a clue.
Opti
the best analyst for CO-Diagnostics. By far.
https://www.globenewswire.com/news-release/2020/08/20/2081387/0/en/What-Facts-Got-to-Do-with-It.html
Opti
Co-Diagnostics nabs U.S. patent covering COVID-19 test
Aug. 20, 2020 6:48 AM ET|About: Co-Diagnostics, Inc. (CODX)|By: Douglas W. House, SA News Editor
The USPTO has issued a new patent to Co-Diagnostics (NASDAQ:CODX) covering its CoPrimer technology used in its COVID-19 test and other molecular assays. The patent, which builds on an earlier patent awarded in October 2018 covering certain applications of the CoPrimer molecule, applies to the physical structure of the molecule.
Shares up 4% premarket on light volume.
Opti
I am holding as I firmly believe it will regain to $30, once the shorts are finished and moved on to destroy another stock.
This has happened before. It is the new market; shorts rule but their time is limited.
Opti